Feng, Po-Hao <br/><br/>
Bevacizumab Reduces S100A9-Positive MDSCs Linked to Intracranial Control in Patients with EGFR-Mutant Lung Adenocarcinoma.  [electronic resource] 

 -  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer  07 2018 
 - 958-967 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1556-1380 
<br/><br/><label>Standard No.: </label>10.1016/j.jtho.2018.03.032  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adenocarcinoma--drug therapy<br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Bevacizumab--administration & dosage<br/>Brain Neoplasms--immunology<br/>Calgranulin B--metabolism<br/>Carcinoma, Non-Small-Cell Lung--drug therapy<br/>ErbB Receptors--genetics<br/>Erlotinib Hydrochloride--administration & dosage<br/>Female<br/>Follow-Up Studies<br/>Gefitinib--pharmacology<br/>Humans<br/>Lung Neoplasms--drug therapy<br/>Male<br/>Middle Aged<br/>Mutation<br/>Myeloid-Derived Suppressor Cells--drug effects<br/>Prognosis<br/>Survival Rate